[Pleuro-pulmonary staphylococcal infection due to heterogenous resistant staphylococcus aureus. Role of the medical bacteriological laboratory].
D000617:Aminoglycosides / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002511:Cephalosporins / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D005260:Female; D005796:Genes; D014644:Genetic Variation; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D008034:Lincomycin / Q000627:therapeutic use; D008826:Microbial Sensitivity Tests / Q000379:methods; D010403:Penicillin Resistance; D010406:Penicillins / Q000494:pharmacology; D011001:Pleuropneumonia / Q000188:drug therapy / Q000209:etiology*; D011815:R Factors; D012462:Saline Solution, Hypertonic; D013203:Staphylococcal Infections / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects*
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D005839:Gentamicins; D010406:Penicillins; D012462:Saline Solution, Hypertonic; D008034:Lincomycin
Staphylococcie pleuro-pulmonaire à staphylocoque doré résistant hétérogène. Rôle du laboratoire de bactériologie médicale